Julien Potet

Mr. Julien Potet

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Toxicon: X
Verified
Journal Article
Open access
Julien PotetJulien Potet
Julien Potet
DBDavid Beran
David Beran
Nicolas RayNicolas Ray
Nicolas Ray
GAGabriel Alcoba
Gabriel Alcoba
AHAbdulrazaq Habib
Abdulrazaq Habib
DWDavid J. Williams
David J. Williams
Access to safe, effective, quality-assured antivenom products that are tailored to endemic venomous snake species is a crucial component of recent coordinated efforts to reduce the global burden of snakebite envenoming. Multiple access barriers may affect the journey of antivenoms from manufacturers to the bedsides of patients. Our review describes the antivenom ecosystem at different levels and identifies solutions to overcome these challenges.

24 June 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Julien PotetJulien Potet
Julien Potet
JSJames Smith
James Smith
LMLachlan McIver
Lachlan McIver
Snakebite envenoming kills more than more than 20,000 people in Sub-Saharan Africa every year. Poorly regulated markets have been inundated with low-price, low-quality antivenoms. This review aimed to systematically collect and analyse the clinical data on all antivenom products now available in markets of sub-Saharan Africa. Our market analysis identified 12 polyspecific and 4 monospecific antivenom products in African markets. Our search strategy was first based on a systematic search of publication databases, followed by manual searches and discussions with experts. All types of data, including programmatic data, were eligible. All types of publications were eligible, including grey literature. Cohorts of less than 10 patients were excluded. 26 publications met the inclusion criteria. Many publications had to be excluded because clinical outcomes were not clearly linked to a specific product. Our narrative summaries present product-specific clinical data in terms of safety and effectiveness against the different species and envenoming syndromes. Three products (EchiTabPlus, EchiTabG, SAIMR-Echis-monovalent) were found to have been tested in robust clinical studies and found effective against envenoming caused by the West African carpet viper (Echis ocellatus). Four products (Inoserp-Panafricain, Fav-Afrique, SAIMR-Polyvalent, Antivipmyn-Africa) were found to have been evaluated only in observational single-arm studies, with varying results. For nine other products, there are either no data in the public domain, or only negative data suggesting a lack of effectiveness. Clinical data vary among the different antivenom products currently in African markets. Some products are available commercially although they have been found to lack effectiveness. The World Health Organization should strengthen its capacity to assess antivenom products, support antivenom manufacturers, and assist African countries and international aid organizations in selecting appropriate quality antivenoms. Snakebite envenomation represents one of the most neglected tropical medical conditions worldwide. Despite high levels of morbidity and mortality associated with snakebite, its neglected nature has compromised the availability and evaluation of antivenom treatment. This review was initiated by Médecins Sans Frontières’ / Doctors Without Borders (MSF) Access Campaign, as the existing antivenom access crisis in sub-Saharan Africa was deepening. This study sought to review the clinical data pertaining to each antivenom product currently available for use in sub-Saharan Africa. 16 different antivenoms were identified. A total of 26 studies met the inclusion criteria. Given the heterogeneity of study methodology and quality, data for individual antivenoms are presented in the form of a narrative analysis. Only two studies reported clinical data collected from randomized controlled trials. Consistent monitoring of the side effects of antivenom treatment was lacking. The absence of good quality data for the majority of antivenoms in sub-Saharan Africa is a major concern. Further robust data collection is required, while urgent investments are needed at the global level to ensure a sustained production of safe and effective antivenom treatment, and its affordable access across sub-Saharan Africa.

19 August 2021 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
EDElin Hoffmann Dahl
Elin Hoffmann Dahl
HHHamdan Mustafa Hamdan
Hamdan Mustafa Hamdan
LMLexson Mabrouk
Lexson Mabrouk
SMSultani Hadley Matendechero
Sultani Hadley Matendechero
TMTesfahun Bishaw Mengistie
Tesfahun Bishaw Mengistie
GAGabriel Alcoba
Gabriel Alcoba

20 December 2022 in Toxicon: X
Verified
Journal Article
Open access
Julien PotetJulien Potet
Julien Potet
SSSaschveen Singh
Saschveen Singh
KRKoert Ritmeijer
Koert Ritmeijer
KSKasaye Sisay
Kasaye Sisay
GAGabriel Alcoba
Gabriel Alcoba
MCMatthew Coldiron
Matthew Coldiron
The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each year. We describe our activities against snakebite in three African countries: Central African Republic, South Sudan and Ethiopia, in which different models of care have been developed. A standard protocol using two different antivenoms depending on the patient's syndrome has been introduced, and a simple blood coagulation test is performed to detect venom-induced coagulopathy. Other services, including surgery for necrotizing wounds, are offered in the facilities where MSF admits a large number of snakebite patients. All services, including provision of antivenom, are offered free-of-charge in MSF-supported facilities. Community-based activities focusing on preventive measures and prompt transport to hospital have been developed in a few MSF projects. The provision of quality care and treatment, including effective antivenoms, without out-of-pocket payments by the patients, probably explains why MSF has admitted an increasing number of snakebite victims over the last years. This model requires significant resources and monitoring, including regular training of healthcare workers on treatment protocols and a considerable budget for antivenom procurement.

18 December 2021 in Toxicon: X
Verified
Journal Article
Open access
GAGabriel Alcoba
Gabriel Alcoba
Julien PotetJulien Potet
Julien Potet
RVRenaud Vatrinet
Renaud Vatrinet
SSSaschveen Singh
Saschveen Singh
CNCarolina Nanclares
Carolina Nanclares
KRKoert Ritmeijer
Koert Ritmeijer
Snakebite envenoming is a public health concern in many countries affected by humanitarian crises. Its magnitude was recognized internationally but associations between snakebite peaks and humanitarian crises were never clearly established or analysed. This scoping review searched any available evidence of this hypothesized association between snakebite types of crises, through PubMed/Medline by two researchers. The search also included hand searching, and reports from humanitarian organizations working in this area.

6 June 2024 in Emergency Medicine Journal
Verified
Journal Article
Open access
PDF file
Julien PotetJulien Potet
Julien Potet